Hot off the Forge
-
Forge CEO Dr. Timothy J. Miller will also join a panel of gene therapy experts for a discussion on “Dosing…
-
Strategic alliance will help advance the development and manufacturing of SGT-003, Solid’s next generation gene therapy program for Duchenne.
-
“We are thankful to have a positive dialogue with the EMA and for gaining alignment with the FDA on the…
-
Juan Ruiz, M.D., Ph.D., M.B.A., joins as Senior Vice President of Medical Affairs, and Frank Agbogbo, Ph.D., M.B.A., joins as…
-
The strategic development and manufacturing partnership will help advance GentiBio’s unique immune tolerance platform.
-
“Forge Forward” aims to train and attract top talent with specialized Good Manufacturing Practice (GMP) training to the company.
-
The presentation features CEO Timothy J. Miller, Ph.D., Chief Medical Officer Maria Escolar, M.D., and Chief Technical Officer David Dismuke,…
-
“John is a seasoned biotech executive, bringing over 20 years of expertise and a proven track record in gene and…
-
Forge’s CEO will provide a company overview, detailing the company’s growth from its launch in July 2020 with $40 million…
-
Dr. David Dismuke, CTO will present, “Development of pEMBR™—An Improved Adenovirus Helper Plasmid for AAV Production.”
-
“We believe that focusing entirely on gene therapy will allow us to best serve our clients and patients by efficiently…
-
Forge Chief Executive Officer, President, CEO Timothy J. Miller, Ph.D., will be joined by David Dismuke, Ph.D., Chief Technical Officer, in…